Gossamer Bio showcases seralutinib studies at PVRI Congress
SAN DIEGO - Gossamer Bio, Inc. (NASDAQ:GOSS), a biopharmaceutical company in the clinical stage with a market capitalization of $225 million, has shared new research findings on its drug candidate ...
Healio2 小时
Winrevair PAH trial stopped due to earlier ‘robust evidence’
The phase 3 HYPERION trial of Winrevair in adults with newly diagnosed pulmonary arterial hypertension functional class two or three is ending early due to robust positive evidence found in previous ...
Gossamer Bio Presented Clinical and Preclinical Data at the Pulmonary Vascular Research ...
Gossamer Bio, Inc. (Nasdaq: GOSS), a clinical-stage biopharmaceutical company focused on the development and ...